Adial Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Adial Pharmaceuticals, Inc. carries a market capitalization of 9.58M, placing it among publicly traded companies globally. Its enterprise value stands at -21.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.58M |
| Enterprise Value | -21.99M |
Share Statistics
Adial Pharmaceuticals, Inc. currently has 2.63M shares outstanding.
| Shares Outstanding | 2.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.18 |
| P/TBV Ratio | -0.18 |
| P/FCF Ratio | -0.53 |
| P/OCF Ratio | -0.53 |
Financial Position
Adial Pharmaceuticals, Inc. maintains a current ratio of 5.63, meaning it holds 5.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.63 |
| Quick Ratio | 5.61 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -591.65 |
| Return on Assets (ROA) | -322.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Adial Pharmaceuticals, Inc.'s stock has declined approximately -59.44444% over the past 52 weeks. The 50-day moving average sits at 4.81, while the 200-day moving average is 3.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | -59.44444% |
| 50-Day Moving Average | 4.81 |
| 200-Day Moving Average | 3.31 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -57.68M, while operating income came in at -57.68M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -57.68M |
| Pretax Income | -57.80M |
| Net Income | -57.80M |
| EBITDA | -57.68M |
| EBIT | -57.68M |
| Earnings Per Share (EPS) | -25.21 |
Balance Sheet
Total book value stands at -38.38M, with working capital of 23.72M providing operational flexibility.
| Cash & Cash Equivalents | 28.71M |
| Total Debt | N/A |
| Net Debt | -28.71M |
| Equity (Book Value) | -38.38M |
| Book Value Per Share | -14.61 |
| Working Capital | 23.72M |
Cash Flow
Adial Pharmaceuticals, Inc. produced -11.13M in operating cash flow over the past twelve months.
| Operating Cash Flow | -11.13M |
| Capital Expenditures | N/A |
| Free Cash Flow | -11.13M |
| FCF Per Share | -4.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -426.17 |
| FCF Yield | -189.66 |
Stock Splits
Adial Pharmaceuticals, Inc.'s most recent stock split took place on February 6, 2026 with a 25:1 split ratio.
| Last Split Date | 2/6/2026 |
| Split Ratio | 25:1 |
Scores
Adial Pharmaceuticals, Inc. posts an Altman Z-Score of -12.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.44 |